Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruitingRare disease

Study of RLS-0071 in Hospitalized Patients with Steroid-Resistant Acute Graft-versus-Host Disease (aGvHD)

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with acute graft versus host disease (aGvHD), a condition that can occur after stem cell transplantation when the donor's immune cells attack the recipient's tissues. The study will test a new medication called RLS-0071, which is given through intravenous infusion, in combination with standard treatments including ruxolitinib.

The main purpose of this research is to determine if RLS-0071 is safe and effective for treating steroid-resistant acute graft versus host disease. The medication will be tested at different dose levels to find the most appropriate dosing. During the study, participants will receive RLS-0071 infusions for up to 14 days while in the hospital.

Throughout the study, doctors will monitor how well the treatment works by checking the condition of affected organs, including the skin, liver, and digestive system. They will also track various health measurements and collect blood samples to understand how the medication works in the body. The total duration of monitoring after treatment will be 180 days to evaluate long-term effects of the medication.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial qualification

    You must be over 12 years old and weigh between 40-140 kg to participate in the trial

    You need to have acute graft versus host disease (aGvHD) and be hospitalized

    Your blood neutrophil count must be above 500/mL without growth factor support

  2. Step 2

    Treatment initiation

    You will receive RLS-0071 through an infusion

    The treatment will be given together with or within 48 hours of starting another medication called ruxolitinib

    The initial treatment period lasts 7 days

    You will need to stay in the hospital for at least one week during the treatment

  3. Step 3

    Monitoring period

    Your response to treatment will be checked at days 7, 14, 28, 56, and 180

    The doctors will monitor changes in your condition, particularly involving your skin, liver, and digestive system

    Blood samples will be taken to measure treatment effectiveness

    Your pain levels, food tolerance, and overall well-being will be assessed

  4. Step 4

    Follow-up evaluations

    The main evaluation of your response will occur at day 28

    Additional check-ups will continue until day 180

    The doctors will monitor your overall health and survival throughout the study period

    The study will track how well you can reduce other medications, especially steroids

Who can join the trial?

14 criteria

  • You must be at least 12 years old
  • Your blood must show recovery after stem-cell transplantation with neutrophils (a type of white blood cells) count above 500/mL for at least 3 consecutive measurements
  • Your neutrophil count must be above 500/mL at screening without using growth factor medications
  • Your weight must be between 40 kg and 140 kg
  • You (or your legal guardian for minors) must provide written informed consent
  • You must be able to communicate effectively with the study team and follow study requirements
  • If you can have children or your partner can become pregnant, you must agree to use effective birth control during the study
  • You must have steroid-resistant acute graft versus host disease (condition not improving after standard steroid treatment)
  • You must have Grade II-IV acute graft versus host disease affecting skin, liver, or digestive system
  • You must be hospitalized or being admitted to hospital
  • You must be able to stay in hospital for at least 1 week from treatment start
  • You must be starting or have recently started ruxolitinib treatment (unless your doctor determines it's not suitable for you)
  • You must be able to start the study medication (RLS-0071) within 48 hours of starting ruxolitinib
  • You cannot plan to change other medications for graft versus host disease during the first 7 days of treatment (though you can receive other necessary medical treatments)

Who cannot join the trial?

12 criteria

  • Age below 12 years or above 75 years
  • Patients with severe organ dysfunction (significant problems with heart, liver, kidneys or lungs)
  • Active, uncontrolled infections
  • Previous participation in other clinical trials within last 30 days
  • Known allergic reactions to similar medications
  • Pregnant or breastfeeding women
  • Patients using medications that could interfere with the study drug
  • Patients with uncontrolled blood pressure or unstable vital signs
  • History of other cancers in the past 2 years (except for successfully treated skin cancer)
  • Patients unable to follow study procedures or provide informed consent
  • Mental conditions that could affect ability to participate in the study
  • Patients with active bleeding disorders
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

RLS-0071 is an investigational medication being studied for the treatment of acute graft versus host disease (aGvHD), a condition that can occur after bone marrow transplantation. This medication is being tested in patients who have not responded well to steroid treatment. The drug is designed to help manage the complications of aGvHD in hospitalized patients. As this is a phase 2 clinical trial, researchers are working to understand how safe and effective this medication is, how it moves through the body, and what the best dosing strategy might be.

What is already known about the treatment

RLS-0071 - An investigational drug currently being studied in clinical trials for the treatment of acute graft versus host disease (aGvHD), particularly in steroid-refractory cases. This medication is undergoing Phase 2 clinical trials to evaluate its safety, tolerability, and effectiveness in hospitalized patients who haven't responded to standard steroid therapy. The exact mechanism of action at the molecular level is still being researched through pharmacokinetic and pharmacodynamic studies, with the primary goal of determining its optimal dosing and overall response rate at 28 days of treatment. While the specific form of administration is not detailed in the provided data, the medication is being tested in a hospital setting with careful monitoring of patient responses and potential side effects.

Investigated diseases

Acute Graft versus Host Disease (aGvHD) - A condition that occurs after bone marrow or stem cell transplantation when the donated immune cells attack the recipient's body tissues. The disease typically develops within the first 100 days after transplantation and primarily affects the skin, liver, and gastrointestinal tract. The condition begins when the transplanted immune cells recognize the recipient's tissues as foreign and launch an immune response against them. Symptoms can include skin rashes, liver dysfunction, and digestive tract problems including diarrhea and abdominal pain. The severity can range from mild to severe, depending on how many organs are affected and to what extent.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-510582-42-00Protocol codeRLS-0071-203Estimated enrolment60 patientsSponsorRealta Life Sciences Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.